Physician profile
Robin Evenson
NPI 1689749004
$2,632.72
in general payments reported to CMS, 2019-2025
25 companies · $192 in 2025
The $192 reported for 2025 was more than what 80% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $798 · 2022: $532 · 2023: $645 · 2024: $466 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.56 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.10 | 2021-2023 | |
| Astellas Pharma US INC | $256.18 | 2023-2024 | Veozah |
| Organon LLC | $238.11 | 2021-2025 | Nexplanon, Jada System |
| Mayne Pharma Commercial LLC | $232.50 | 2021-2025 | |
| Exeltis, USA INC. | $218.97 | 2021-2024 | Slynd |
| Pfizer INC. | $134.82 | 2021-2023 | |
| Daiichi Sankyo INC. | $116.05 | 2021-2022 | |
| Millicent US INC | $112.18 | 2021-2024 | Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $110.72 | 2022-2024 | |
| Mylan Pharmaceuticals INC. | $101.27 | 2021-2022 | |
| Agile Therapeutics, INC. | $89.28 | 2022-2024 | Twirla |
| Therapeuticsmd, INC. | $84.93 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $76.74 | 2023 | Myfembree |
| Myriad Women'S Health, INC. | $71.72 | 2023 | Myrisk |
| Biohaven Pharmaceuticals, INC. | $47.08 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.75 | 2023 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $32.46 | 2022-2024 | Novasure |
| Coopersurgical, INC. | $23.49 | 2025 | Paragard T 380a |
| Biogen, INC. | $22.68 | 2024 | Zurzuvae |
| Pacira Pharmaceuticals Incorporated | $21.12 | 2021 | |
| Integra Lifesciences Corporation | $18.52 | 2023 | Biodrestore, Medihoney, Biodfactor |
| Roche Diagnostics Corporation | $17.86 | 2021 | |
| Scynexis, INC. | $16.16 | 2022 | |
| Avion Pharmaceuticals | $15.95 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Evenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.